Italy

Banca d'Italia: Expert Assessment in Credit Rating System

The Bank of Italy has published an analysis (N. 79) detailing recent methodological improvements to its internal credit rating system for non-financial companies (ICAS). The study, based on over 25,000 expert assessments from 2016-2022, highlights how expert judgment, including climate and sector risk analysis, significantly enhances rating predictive power and stability during economic stress.

AI and US Economy: Accounting Perspective on Investment and Production

The Bank of Italy has published a paper analyzing the impact of Artificial Intelligence (AI) infrastructure investments on the US economy. The paper details how AI investments, particularly in data centers, have supported aggregate demand in the US and discusses the global supply chain for AI components.

AI Adoption Impact on Italian Firms' Productivity and Profitability

Banca d'Italia published a paper analyzing the economic impact of AI adoption on Italian firms. The study found that AI adoption increases productivity and profitability, leading to a reallocation towards more qualified roles without negative overall employment effects.

Italian Less Significant Banks' Corporate Lending Deterioration Analysis

Banca d'Italia published an analysis on corporate lending by Italian less significant banks (LSI) compared to significant groups (SI). The study found that LSIs have a higher loan deterioration rate, largely due to a greater proportion of loans to smaller, higher-risk businesses.

PRAC Recommendations on Safety Signals

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has adopted recommendations on safety signals discussed between September 29 and October 2, 2025. These recommendations are directly actionable by marketing authorisation holders (MAHs) for both Centrally Authorised Products (CAPs) and Nationally Authorised Products (NAPs).

PRAC Recommendations on Safety Signals

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has adopted recommendations on safety signals discussed in February 2026. These recommendations require marketing authorisation holders (MAHs) to provide supplementary information or take regulatory action, such as updating product information.

PRAC Recommendations on Signals - January 2026 Meeting

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has adopted recommendations on safety signals discussed in January 2026. Marketing Authorisation Holders (MAHs) for affected medicinal products are required to update product information within specified timelines.

PRAC Recommendations on Safety Signals

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has adopted recommendations on safety signals discussed in November 2025. Marketing Authorisation Holders (MAHs) are required to provide supplementary information or update product information based on these recommendations, with specific deadlines for certain signals.

PRAC Recommendations on Safety Signals

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has adopted recommendations on safety signals discussed in their October 2025 meeting. These recommendations are directly actionable by marketing authorisation holders (MAHs) for updates to product information.

AGCM Investigates Procter & Gamble for Misleading Braun Ads

The Italian Competition Authority (AGCM) has launched an investigation into Procter & Gamble S.r.l. concerning misleading advertising for the Braun Skin i-Expert hair removal device. The authority is concerned that claims of being 'hair-free for two years' may overstate the product's effectiveness and lack sufficient evidence.